| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/22/2005 | WO2005086806A2 An advertisement method |
| 09/22/2005 | WO2005086763A2 Stable injectable compositions |
| 09/22/2005 | WO2005086697A2 Materials for medical implants and occlusive devices |
| 09/22/2005 | WO2005086694A2 Occlusive biomedical devices, punctum plugs, and methods of use thereof |
| 09/22/2005 | WO2005086641A2 Anti-infectious hydrogel compositions |
| 09/22/2005 | WO2005086639A2 Improved efficacy and safety of targeted particulate agents with decoy systems |
| 09/22/2005 | WO2005079756A3 Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| 09/22/2005 | WO2005072736A3 Stable gabapentin compositions |
| 09/22/2005 | WO2005072064A3 A preparation, process and a regenerative method and technioue for prevention, treatment and glycemic control of diabetes melletus |
| 09/22/2005 | WO2005068498A3 Human therapeutic cells secreting nerve growth factor |
| 09/22/2005 | WO2005065069A3 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| 09/22/2005 | WO2005063232A8 Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity |
| 09/22/2005 | WO2005062722A3 Fexofenadine containing pharmaceutical formulation |
| 09/22/2005 | WO2005046567A3 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same |
| 09/22/2005 | WO2005041976B1 Injectable gabapentin compositions |
| 09/22/2005 | WO2005041869A3 Process for co-spray drying agents with dry silicified mcc |
| 09/22/2005 | WO2005025503A3 A composition and method of treatment for urogenital conditions |
| 09/22/2005 | WO2005023184A3 Antibiotic product, use and formulation thereof |
| 09/22/2005 | WO2005020957A3 Stepwise delivery of topiramate over prolonged period of time |
| 09/22/2005 | WO2005007223A3 Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
| 09/22/2005 | WO2005007169A3 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition |
| 09/22/2005 | WO2005007131A3 Propofol formulations with non-reactive container closures |
| 09/22/2005 | WO2005007069A3 Soft gel formulations for saquinavir |
| 09/22/2005 | WO2004071451A3 Random alkylene oxide copolymers for medical and surgical utilities |
| 09/22/2005 | WO2004064833A8 Clindamycin phosphate foam |
| 09/22/2005 | WO2004060265A3 Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 09/22/2005 | WO2004037222A3 Sustained-release tramadol formulations with 24-hour efficacy |
| 09/22/2005 | US20050209733 Automatic medicament dispenser system |
| 09/22/2005 | US20050209666 Electrical devices and anti-scarring agents |
| 09/22/2005 | US20050209665 Electrical devices and anti-scarring agents |
| 09/22/2005 | US20050209606 Alginate viscoelastic composition, method of use and package |
| 09/22/2005 | US20050209556 Implantable intravascular delivery device |
| 09/22/2005 | US20050209551 Detoxification and breast health preparations |
| 09/22/2005 | US20050209345 Lymphatic drug delivery system |
| 09/22/2005 | US20050209343 Percutaneous absorption promoters and compositions for treating athlete's foot |
| 09/22/2005 | US20050209315 Bioavailable nutritional supplement and method of treatment of malabsorption |
| 09/22/2005 | US20050209229 Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib |
| 09/22/2005 | US20050209218 NMDA receptor antagonist is memantine in sustained release dosage form, and a second agent is despramine, escitalopram, paroxetine, venlafaxine, duloxetine, buspirone, or bupropion as antidepressant, a carrier; for treating depression, bipolar depression, anxiety, pain, neuropathies, epilepsy, dementias |
| 09/22/2005 | US20050209207 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery |
| 09/22/2005 | US20050209206 Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier |
| 09/22/2005 | US20050209203 Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease |
| 09/22/2005 | US20050209190 Camptothecin complexes |
| 09/22/2005 | US20050209185 Synergistic mixture; administering by inhalation; tiotropium bromide; metered dose inhaler, a dry powder inhaler; asthma, chronic obstructive pulmonary disease |
| 09/22/2005 | US20050209171 Treatment of periodontal disease |
| 09/22/2005 | US20050209170 Consists of plant indoles, flavonoids, polyphenols, stilbenes, D-glucaric acid, triglycerides and phospholipids; prostate and breast cancer; for the heavy metal detoxification of humans and animals |
| 09/22/2005 | US20050209159 Effectors of dipeptidyl peptidase IV for topical use |
| 09/22/2005 | US20050209144 Protein formulations |
| 09/22/2005 | US20050209099 One step dry powder blending of emulsions, solutions, or suspensions of drugs or diagnostic imaging agents without intermediate collection and blending steps; increased efficiency; industrial scale |
| 09/22/2005 | US20050208648 Minimally invasive microfluidic apparatus for monitoring lactate and/or glucose in bodily fluids |
| 09/22/2005 | US20050208589 Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
| 09/22/2005 | US20050208228 Electrostatic application of powder material to solid dosage forms |
| 09/22/2005 | US20050208200 Multilayer, biocompatible overcoatings containing heparin; stents |
| 09/22/2005 | US20050208154 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily |
| 09/22/2005 | US20050208148 Method of reducing risk of infection of a bovine teat after cessation of milking |
| 09/22/2005 | US20050208146 Novel dosage and administration method for oral camptosar |
| 09/22/2005 | US20050208145 beta-glucan concentrate has a honeycomb structure; subjecting the fiber residue from oat or barley flour/alcohol slurry to sonication, protease or amylase treatment or combination treatment; use as encapsulating agent; absorption or release of drug in lower intestinal tract; sustained release |
| 09/22/2005 | US20050208143 made of a biodegradable polymer formed using cationic or anionic detergent the surfaces of which adsorb biologically active macromolecules, such tumor antigens; vaccine delivery |
| 09/22/2005 | US20050208142 Production of nanoparticles having a defined number of ligands |
| 09/22/2005 | US20050208140 A di, tri or oligopeptide covalently bonded with an active agent ( therapeutical agent, contrast agent or fluorescent dye) from a side chain of the intermediate or C-terminus amino acid |
| 09/22/2005 | US20050208139 comprising Z isomeric form and E isomeric form of 4-hydroxy tamoxifen; not affected the drug potency; drug mixture in a gel, a solution, patch, in a unit dose packet or in a multiple dose container with a metered pump; new drug form; drug delivery device |
| 09/22/2005 | US20050208138 Injection of a biocompatible polymer, polysaccharide or polyamino acid, a cross-linker, and therapeutic agent into tumor; hydrogel formed in the tumor retains the therapeutic agent; drug delivery method; sustained releasing the biodrug |
| 09/22/2005 | US20050208137 comprising angiogenesis inhibitor retinoic acid, taxol and polymeric carrier polylactone; treating cancer, angiogenic-dependent diseases, embolizing blood vessels, and eliminating biliary, urethral, esophageal, tracheal/bronchial obstructions, corneal neovascularization; coated stents with the mixture |
| 09/22/2005 | US20050208136 Antitumor agent and process for producing the same |
| 09/22/2005 | US20050208135 Monocompartment osmotic controlled drug delivery system |
| 09/22/2005 | US20050208134 Each bead comprising core compartment containing water-in-oil emulsion surrounded by a polymeric shell; for use in polymeric delivery systems that provide sustained release of bioactive compound, in particular, a quinazolinone compound such as halofuginone; angiogenesis, prevention of tumor growth |
| 09/22/2005 | US20050208133 Provides site-specific release of drug to both small intestine and colon in form of multiple controlled doses for long-lasting efficacy, thereby reducing drug dosing frequency; drug core comprising first drug and saccharide coated by organic acid-soluble polymer, enteric coating polymer and second drug |
| 09/22/2005 | US20050208130 Tablet formulations comprising valsartan |
| 09/22/2005 | US20050208129 Prolonged release bioadhesive therapeutic systems |
| 09/22/2005 | US20050208128 Immediate release tablet |
| 09/22/2005 | US20050208127 Comprises D-mannitol having average particle diameter of 31-80 mu m, active ingredient, disintegrant, and stearic acid or metallic stearate in an amount of 0.01-0.5% by weight; rapidly disintegrates in oral cavity; method of external lubricating compression makes porosity small, enables small tablet |
| 09/22/2005 | US20050208126 Chemical ifg-i composition for the treatment and prevention of neurodgenerative diseases |
| 09/22/2005 | US20050208123 Vaccine comprising a major outer membrane protein from chlamydia and a mucosal adjuvant such as a combination of QS21 and 3D-MPL, or chlorea toxin or heat labile enterotoxin; provides protection from Chlamydia induced infertility |
| 09/22/2005 | US20050208122 Biodegradable biocompatible implant and method of manufacturing same |
| 09/22/2005 | US20050208120 artificial antigen presenting cell comprising liposome comprising a fluid lipid bilayer; MHC class I and/or class II molecule associated with the bilayer complexed with an antigenic peptide; and accessory molecules associated with the bilayer; for treating autoimmune disorders, allergies, cancers, etc. |
| 09/22/2005 | US20050208119 Preparations of chelating agents encapsulated in micelles or liposomes; comprising alpha lipoic acid and micelles or liposomes containing EDTA or other chelators and magnesium chloride; for transferring antioxidant and chelating agent, across cell membrane; therapy for toxic heavy metal poisoning |
| 09/22/2005 | US20050208118 Preparations of chelating agents encapsulated in micelles or liposomes; comprising alpha lipoic acid and micelles or liposomes containing EDTA or other chelators and magnesium chloride; for transferring antioxidant and chelating agent, across cell membrane |
| 09/22/2005 | US20050208117 Analgesic, non-rate controlled, monolithic, subsaturated patch; sufficient to induce and maintain analgesia in a human for at least three days |
| 09/22/2005 | US20050208116 Active substance is dissolved in both layers, the affinity of first layer for active substance being 1.15-10 times lower than that of second layer; percent saturation of active substance in both layers is same and is less than 100%; device is simple and can provide stable delivery over a long period |
| 09/22/2005 | US20050208115 Use of treatment system for effectively delivering systemic medications and combining exothermic pad with holding means for providing controlled, reproducible, continuous heat delivery to surface of skin or subcutaneously at constant temperature for specific periods of time; thermoplastic elastomer pad |
| 09/22/2005 | US20050208113 Article having a lotioned topsheet |
| 09/22/2005 | US20050208112 Article having a lotioned topsheet |
| 09/22/2005 | US20050208110 Rapidly dissolving film for delivery of an active agent |
| 09/22/2005 | US20050208109 Non-glue based moisturizing device |
| 09/22/2005 | US20050208108 Hydroxypropyl cellulose and a fatty alcohol (myristyl alcohol); film is edible and disperses upon contacting the film to the eater's tongue; drug delivery |
| 09/22/2005 | US20050208106 Composition containing oat straw and willow herb extract |
| 09/22/2005 | US20050208102 Sustained release delivery systems; contact lens shape; includes vision correction; lower dosage antiangiogenesis therapeutics; reduced local inflammation and/or adverse systemic reactions; macular degeneration; retinopathies |
| 09/22/2005 | US20050208096 Color-fast radiation sterilized implants and precursors thereof |
| 09/22/2005 | US20050208095 Implanting a medical device by infiltrating a tissue of a host near the implant with an antifibrotic agent, and/or an antiinfective agent and/or a polymer; prevention of surgical adhesions |
| 09/22/2005 | US20050208092 Drug delivery; vascular disease; stents, grafts, anastomotic devices, perivascular wraps, sutures and staples |
| 09/22/2005 | US20050208083 Decrease infectivity, morbidity, and/or mortality associated with pathogenic exposure while minimizing microbial resistance, toxicity to the recipient |
| 09/22/2005 | US20050208082 Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| 09/22/2005 | US20050208080 Sandwiched oatmeal biscuits supporting cream filling containing antiobesity dosage unit |
| 09/22/2005 | US20050208076 Combined with recombinant human serum albumin |
| 09/22/2005 | US20050208035 Nutritional composition for treating an immune condition |
| 09/22/2005 | US20050208034 Pau D' Arco, La Pacho, tabebuia heptaphylla, lactobacillus acidophilus, bifidobacterium bifidum, bifidobacterium longum, streptococcus thermophilus, lactobacillus bulgaricus, lactobacillus bulgaricus, lactobacillus paracasei, allium sativum or concentrated Garlic bulb; ingested orally |
| 09/22/2005 | US20050208028 Nutrient Medium for maintaining neural cells in injured nervous system |
| 09/22/2005 | US20050208014 In situ formation of a polymeric cyanoacrylate film containing mixed antibiotics applied as a liquid or gel to the skin surface |
| 09/22/2005 | US20050208003 ascorbic acid compositions that stabilize unusually large concentrations of vitamin C and vitamin E |
| 09/22/2005 | US20050207994 Base for oral composition and the oral composition |
| 09/22/2005 | US20050207993 chewing gum or edible thin films containing polyphenolic apple extracts, used for binding pyridine in the mouth of an individual after smoking tobacco products |